Medlab Clinical Share Price and Company Fundamentals



Price
$0.17
Change
0.000 (0.000%)
52 week
0.135 - 0.42

Last traded: Today at 5:53 AM

Medlab Clinical Limited, a medical research and development facility, engages in the nutraceutical products and pharmaceutical research businesses in Australia. The company develops bio-therapeutics for chronic kidney diseases, pre-diabetes/obesity, depression, musculoskeletal muscle loss associated with ageing, and non-opioid pain management. It also provides nutraceuticals for anti-inflammatory, cardiovascular support, endocrine support, gastrointestinal support, immunological support, infants and toddlers, metabolic support, musculoskeletal support, neurological support, sports performance, urogenital support, and weight management, as well as for men, pregnancy, seniors, teenagers, and women support. Medlab Clinical Limited was founded in 2012 and is headquartered in Botany, Australia.

Key Metrics

PE ratio

-

PB ratio

5.86

Dividend yield

Beta

1.15

Market cap

$58.17M

Enterprise value

$42.61M

Company profile

Primary activitiesNutritional pharmaceutical research and development.
Industry / SectorBiotechnology / Healthcare
Websitehttp://www.medlab.co
Mailing address66 McCauley Street Alexandria NSW 2015 Australia
Phone / Fax61 2 8188 0311 / 61 2 9699 3347
Share registryADVANCED SHARE REGISTRY SERVICES

Dividends

Medlab Clinical does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Medlab Clinical.

NameTitleAgeTotal Pay
Dr. Sean Michael HallCEO & Director379.11k
Mr. Ian CurtinsmithChief Information Officer71.2k
Mr. Drew Anthony TownsendCompany Sec. & Non-Exec. Director5560.23k
Dr. Luis Vitetta BSc(Hons), Grad Dip, Ph.D., Grad Dip NutrDirector of Medical Research304.07k
Dr. David A. RutoloDirector of Science192.44k
Mr. Simon AllsopChief Financial Officer
Mr. Tony PotterDirector of Pharmaceuticals Sales, Marketing & Education

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-392.42%

Return on assets

-44.05%

Return on equity

-113.42%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Medlab Clinical is 58.17M and its enterprise value is 42.61M. The enterprise value to revenue ratio of MDC is 14.47.

The MDC's stocks Beta value is 1.15 making it 15% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Medlab Clinical (MDC)

Medlab Clinical (ASX:MDC) Frequently Asked Questions

1. What is Medlab Clinical's Stock Symbol?

Medlab Clinical trades on ASX under the ticker symbol "MDC".

2. What is Medlab Clinical's stock price today?

One share of MDC stock can currently be purchased for approximately $0.17.

3. How can I contact Medlab Clinical?

Medlab Clinical's mailing address is 66 McCauley Street Alexandria NSW 2015 Australia. The company can be reached via phone at 61 2 8188 0311.

4. What is Medlab Clinical's official website?

The official website of Medlab Clinical is http://www.medlab.co.

5. Which share registry manages Medlab Clinical's stock?

Medlab Clinical's stock is managed by ADVANCED SHARE REGISTRY SERVICES.